Explainable Plasma Proteomics-Based Machine Learning for Osteoporosis Diagnosis, Prognosis, and Protein Biomarker Discovery in the UK Biobank.

Authors

Wenxiang Zhang, Wenjing Zhang, Hanwen Cheng, Weijie Gong, Yuhui Kou, Baoguo Jiang

Published in

FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Volume 40. Issue 17. Pages e72201. Sep 15, 2026.

Abstract

Osteoporosis (OP) is often underdiagnosed, highlighting the need for tools that can both detect existing disease and predict future risk; large-scale plasma proteomics combined with explainable machine learning enables integrated diagnostic and prognostic modeling while prioritizing clinically relevant protein markers. This study aims to develop and validate an explainable plasma proteomics machine-learning framework for osteoporosis diagnosis, future risk prediction, and biomarker discovery. We further tested whether a combined marker panel could distinguish normal, prevalent OP, and future incident OP states from baseline samples. Using UK Biobank plasma proteomic data, we established SPX-OP, which separately models prevalent OP and incident OP based on Extreme Gradient Boosting (XGBoost) and SHapley Additive exPlanations (SHAP), and then evaluates whether the union of diagnostic and prognostic markers supports integrated baseline stratification. In the experiments, both the diagnostic and prognostic XGBoost models showed robust discrimination for osteoporosis status and future risk, respectively. SHAP-derived protein markers, including FSHB, ADIPOQ, SOST, COL9A1, and CHAD, were linked to osteoporosis and enriched in bone-related pathways involving bone development and remodeling, extracellular matrix organization, and inflammatory processes. Using only these SHAP-selected protein markers, the XGBoost model outperformed the full-proteome models and provided robust, simultaneous diagnostic and prognostic prediction of osteoporosis. In summary, this work transforms high-dimensional proteomic data into interpretable marker sets, paving the way for improved risk stratification and further validation of plasma protein biomarkers in osteoporosis.

PMID:
42667149
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.